NYON, Switzerland, Dec. 3, 2008 (GLOBE NEWSWIRE) -- Mymetics Corporation (OTC BB:MYMX.OB - News) announced today that Khandaker Partners has initiated coverage (http://www.mymetics.com) with an intermediate term price range of $1.20 for its common stock. Mymetics is a Swiss biotech company with a mucosal AIDS vaccine candidate entering Human Clinical Phase I trials and a long term Malaria vaccine in Phase II Human Clinical trials.
